granulocyte-colony stimulating factor (GCSF) / University of Bristol - LARVOL DELTA

Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial. (PubMed, J Clin Oncol) - "In this study of older patients with AML considered fit and with evidence of residual disease after first induction, chemotherapy intensification improved survival. DAC intensification was better tolerated than FLAG-Ida."

Journal • Residual disease • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Transplantation

An open-label pilot study of recombinant granulocyte-colony stimulating factor in Friedreich's ataxia. (PubMed, Nat Commun) - "Here we perform an open-label, pilot study of recombinant human granulocyte-colony stimulating factor (G-CSF) administration in seven people with FA (EudraCT: 2017-003084-34); each participant receiving a single course of G-CSF (Lenograstim; 1.28 million units per kg per day for 5 days). Notably, sustained increases in cellular frataxin concentrations and raised PGC-1α and Nrf2 expression are detected. Our findings show potential for G-CSF therapy to have a clinical impact in people with FA."

Journal • Ataxia • CNS Disorders • Friedreich ataxia • Movement Disorders • NFE2L2